#USA #New York #Class Action #Levi & Korsinsky #ESSA Pharma

Alert for ESSA Pharma Inc. Investors

Levi & Korsinsky, a well-known law firm specializing in securities litigation, has recently notified investors of a pending class action lawsuit against ESSA Pharma Inc. (NASDAQ: EPIX). This action is aimed at those who have been adversely affected by alleged securities fraud between December 12, 2023, and October 31, 2024.

What You Should Know

The class action lawsuit seeks to recover losses suffered by shareholders during the specified timeframe. Allegations have been made that ESSA Pharma misled investors regarding the efficacy of its cancer treatment, masofaniten, in combination with enzalutamide. Investors claim that the company overstated the clinical and commercial prospects of this combination therapy, and the shares have suffered as a consequence of misleading statements.

The lawsuit outlines several key points:
1. Efficacy Debate: Claims suggest that the combination of masofaniten with enzalutamide did not exhibit a notable efficacy advantage over enzalutamide alone, contradicting prior statements made by the defendants.
2. Study Challenges: The M-E Combination Study, pivotal in assessing the therapy's success, is said to have been unlikely to meet its primary endpoint, bringing into question the validity of ESSA's public promises regarding treatment outcomes.
3. False Public Statements: Due to these issues, it is argued that the defendants’ public statements were materially false and misleading, impacting investor decisions and stock performance.

Upcoming Deadlines

For investors who sustained losses during the relevant period, the lead plaintiff deadline is set for March 25, 2025. It’s crucial for affected individuals to act promptly if they wish to be considered for a role in the lawsuits as lead plaintiff. Nevertheless, participation does not mandate serving in this leadership position; even class members can still potentially share in any recovery offered by the court.

No Cost to Participate

One of the most significant aspects of this announcement is that there are no upfront costs to class members participating in the lawsuit. Investors can claim compensation without incurring out-of-pocket expenses or fees, given that the firm approaches the funding of these lawsuits without financial barriers to entry.

Why Choose Levi & Korsinsky

Levi & Korsinsky has an impressive track record in handling investor claims and litigating high-stakes cases. Over the last two decades, they have recovered hundreds of millions of dollars for shareholders, proving to be a trustworthy advocate in complex securities litigation. Recognized consistently as one of the leading firms for this kind of legal action as evidenced by their placement in ISS Securities Class Action Services' Top 50 Report, investors can have confidence in their approach.

Next Steps for Investors

Investors who believe they are affected by the alleged fraudulent activities of ESSA Pharma Inc. can gather more information and begin to prepare their claims by accessing the submission form provided by Levi & Korsinsky. By following through on these opportunities, they can actively participate in seeking fairness and potential recovery for their investments.

As the March 25, 2025 deadline approaches, all concerned investors are encouraged to engage and ensure they are informed of their rights and options amidst this significant class action lawsuit. For further inquiries, interested parties should consider reaching out directly to Levi & Korsinsky for personalized assistance and guidance through this process.